"We listen.
If it matters to you, it matters to us"
Daniel J Farrugia MD PhD FACS
Surgeon & Founder, BodyLuxe™
It is a privilege to assist you.
Dr. Daniel Farrugia recognizes that deciding to undergo body contouring surgery and select a plastic surgeon for your procedure can be frightening and overwhelming. He considers it a privilege to assist patients achieve a particular look they desire.
Dr. Farrugia is board-certified by the American Board of Surgery. Dr. Farrugia was inducted as a fellow of the prestigious American College of Surgeons (FACS). He is a fellow of the American Academy of Cosmetic Surgery.
Dr Farrugia connects with his patients from all over the United States on a personal and relatable level, delivering expertly tailored treatment plans alongside a warm and empathetic bedside manner. With a calm and inviting demeanor, Dr. Farrugia’s patients view him not only as a trusted provider but as a friend.
Daniel J Farrugia MD PhD FACS
Surgeon & Owner, BodyLuxe PLLC
Dr. Farrugia has performed several thousands of body contouring procedures and transformed the lives of that many patients. He has mastered the art and science of awake body contouring procedures.
Prior to devoting all his time to his BodyLuxe practice using the latest body contouring technology, he was the main surgeon in the Chicago office of Elite Body Sculpture, later known as AirSculpt, and Aesthetic Physicians PC. During his time there, he was asked to train plastic surgeons in the art of awake body contouring.
Dr. Farrugia is a deeply caring surgeon who listens carefully to his patients and is dedicated to delivering outstanding surgery results. Above all, he is committed to providing safe and appropriate care to his patients and continuously strives to maintain up-to-date techniques and the latest innovations through continuing surgical education.
Dr Farrugia hopes that his legacy will be the hearts and minds of the people he touched with his skill.
You define beauty. We help you achieve it.
Transparency and Trust
Providing safe, compassionate care in the most comfortable and luxurious environment possible.
Dr Daniel Farrugia
Founder, BodyLuxe
U.S. States
Countries
Verified Reviews
An Open and Honest Approach
Discover What's Next
Your most beautiful and confident life is waiting to be discovered with personalized treatment at BodyLuxe by Dr. Farrugia. Our open and honest approach fosters a meaningful patient-doctor relationship and a profound understanding of each individual’s desired outcome.
Consultations
Fat Transfer
Awake Procedures
A Philosophy of Balance
Beyond Surgery
Dr. Farrugia believes in a comprehensive approach to aesthetics to achieve the enhancements that complement your unique beauty.
-
Comprehensive Approach
Dr Farrugia prioritizes understanding your individual needs, concerns, and lifestyle to develop your personalized treatment plan.
-
A Passion for Innovation
Dr. Farrugia is a leader in his field, constantly seeking new advancements and techniques to provide patients with the best possible outcomes.
-
Dedication to Patient Care
Dr. Farrugia's dedication to his patients extends far beyond the operating room. He fosters a warm and welcoming environment where open communication and trust are paramount. His friendly and approachable demeanor puts patients at ease, allowing them to ask questions and voice their concerns openly.
-
Focus on Safety
Our choice to perform our minimally-invasie body contouring procedures awake using the latest technology is conducive to ensuring your safety, optimal outcome, natural result and quick recovery.
Google Review
They are very thorough in explaining the pre-op and post-op and make sure you know that the lines of communication are always open. Dr. Farrugia takes pride in his work and cares for his patients. So glad I decided to go with him.
Google Review
I could not be happier 3 months after my procedure with Dr Farrugia. I went in wanting body sculpting but still wanting to look as natural as possible. He gave me exactly what I asked for, curves in all the right places.
Google Review
Dr Farrugia's Research
Research & Awards
Dr. Farrugia is the author of numerous articles of original research in peer-reviewed international journals which have been subsequently cited by over 1,600 biomedical research teams in their work. He has also presented over 27 works at various regional and international conferences.
Dr. Farrugia received numerous competitive awards throughout his career including a prestigious research fellowship award by the United States Department of Defense, a Merit Award by the Conquer Cancer Foundation, two travel scholarship awards by the Society of Vascular Surgery and American Association for Cancer Research, and an Outstanding Academic Achievement Award by the Department of Surgery at the University of Florida.
Peer-Reviewed Publications
PEER-REVIEWED PUBLICATIONS IN INTERNATIONAL MEDICAL JOURNALS
Brian J Gebhardt, MD; Joel Thomas, BA; Zachary D Horne, MD; Colin E Champ, MD; Daniel J Farrugia, MD, PhD; Emilia Diego, MD; Gretchen M Ahrendt, MD; Sushil Beriwal MD. Is Completion Axillary Lymph Node Dissection Necessary in Patients Underrepresented in ACOSOG Z0011 Trial? Adv Radiat Oncol. 2018 Apr 24;3(3):258-264
Landmann A, Daniel J Farrugia, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R. Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? Am J Clin Pathol. 2018 May 8. doi: 10.1093
Clark BZ, Daniel J Farrugia, Landmann A, Diego EJ, Dabbs DJ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R. Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. Am J Clin Pathol. 2018 Mar 7;149(4):332-343
Daniel J Farrugia, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Lembersky BC, Ahrendt GM, McAuliffe PF, Bhargava R. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol. 2017 Aug;30(8):1078-1085
Daniel J Farrugia, Fischer TD, Delitto D, Spiguel L, Shaw CM. Improved National Quality Database Breast Cancer Care Metrics Following Implementation of a Standardized Tumor Board Note Template. J. Oncol. Pract 2015 11:209-212
Walker LC, Whiley PJ, Couch FJ, Daniel J Farrugia, Healey S, Eccles DM, Lin F, Butler SA, Goff SA, Thompson BA, Lakhani SR, Da Silva LM; kConFab Investigators, Tavtigian SV, Goldgar DE, Brown MA, Spurdle AB. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Human Mutation. 2010 Jun;31(6):E1484-505.
Daniel J Farrugia, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, Wadum L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE, Couch FJ. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Research. 2008 May 1;68(9):3523-31.
D’Assoro AB, Busby R, Acu ID, Quatraro C, Reinholz MM, Daniel J Farrugia, Schroeder MA, Allen C, Stivala F, Galanis E, Salisbury JL. Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene. 2008 Feb 11
Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Daniel J Farrugia, Couch FJ, Urban N, Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008 Feb 28; 451 (7182): 1116-20
Lovelock P, Spurdle A, Mok M, Daniel J Farrugia, SR Lakhani, S Healey, S Arnold, D Buchanan, kConFab Investigators, FJ Couch, BR Henderson, DE Goldgar, SV Tavtigian, G Chenevix-Trench and M Brown. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Research. 2007 Nov 26;9(6):R82
Wu K, Hinson SR, Ohashi A, Daniel J Farrugia, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Research. 2005, Jan; 65(2):417-26.
Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Daniel J Farrugia, Kaufmann SH, Gores GJ. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Research. 2004, May; 64(10):3517-24.
D’Assoro AB, Busby R, Suino K, Delva E, Almodovar-Mercado GJ, Johnson H, Folk C, Daniel J Farrugia, Vasile V, Stivala F, Salisbury JL. Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. Oncogene. 2004, May; 23(23):4068-75.
PH.D. THESIS – INHERITED BREAST CANCER
Daniel J Farrugia . Ph.D. Thesis. Influence of inherited missense mutations on BRCA2 function. Functional studies of the DNA-binding domain of BRCA2 (Dec 2007) Mayo Clinic College of Medicine, Rochester, Minnesota
ORAL PRESENTATIONS & INVITED LECTURES
Daniel J Farrugia (October 2006) BRCA2 and Centrosome Dynamics: Centrosome amplification and aberrant function in response to disruption of BRCA2. Mayo Clinic College of Medicine Symposium; Rochester, MN.
Daniel J Farrugia, Walsh MF, Boughey JC. (October 2008) Severe Radiation Changes after Lumpectomy and Radiation for Breast Cancer Requiring Mastectomy with Flap Coverage. Minnesota Surgical Society 2008 Fall Meeting; Alexandria, MN.
Daniel J Farrugia (Sep 10, 2015) Lecture on Breast Cancer to Surgical Oncology Fellows. University of Pittsburgh Medical Center
Daniel J Farrugia (December 2015) Role of Postmastectomy Radiation Therapy in Breast Cancer. Society of Surgical Oncology Breast Fellowship Webinar.
Daniel J Farrugia (April 2016) Functional Classification of Variants of Uncertain Significance in Breast Cancer Predisposition Genes in an Era of Personalized Medicine: Opportunities and Challenges. Invited lecture from Sylvester Comprehensive Cancer Center, University of Miami.
Daniel J Farrugia (October 2016) Breast Surgery. Invited lecture at Centegra Physician Care 2016 Combined Provider Forum. Huntley, IL.
Daniel J Farrugia (February 2017) The evolving personalized medicine approach to breast cancer. Invited lecture at Health Strong Woman Event Lunch and Learn. Crystal Lake, IL.
Daniel J Farrugia (October 2017) Breast Cancer. Radio Interview on 105.5 FM Woodstock, IL.
Daniel J Farrugia (May 2018) A Lymphedema Management Program for Tomorrow. 1 hour CME Lecture for Lymphedema Therapists, Centegra Sage Cancer Center, McHenry, IL.
Daniel J Farrugia (May 2018) The Breast Cancer Answers You Need. Centegra Health Bridge, Crystal Lake, IL.
Daniel J Farrugia (July 2018) Why do Women Get Breast Cancer. 1 hour CME Lecture for Mammography Technologists, Centegra Gavers Breast Center, Crystal Lake, IL.
SCIENTIFIC ABSTRACTS
Farrugia DJ and Couch FJ. (October 2005) Evaluation of BRCA2 missense mutations in the DNA-binding domain of BRCA2. Mayo Clinic Symposium; Rochester, MN.
Farrugia DJ, Ohashi A, Agarwal MK, and Couch FJ. (July 2006) Cancer Risk Assessment and Functional Evaluation of Inherited BRCA2 Missense Mutations. American Association for Cancer Research Pathobiology of Cancer Meeting; Snowmass, CO.
Farrugia DJ, Goldgar DE, Tavtigian SV, Wadum L, Johnson K, Mentlick J, Lindor N, and Couch FJ. (June 2008) Clinical Classification of BRCA1 and BRCA2 Variants of Uncertain Significance. Department of Defense Era of Hope Breast Cancer Research Program Meeting, Baltimore, MD
Farrugia DJ, Walsh MF, Boughey JC. (October 2008) Severe Radiation Changes after Lumpectomy and Radiation for Breast Cancer Requiring Mastectomy with Flap Coverage. Balfour Surgical Symposium, Mayo Clinic; Rochester, MN.
Farrugia DJ, Goldgar DE, Tavtigian SV, Wadum L, Johnson K, Mentlick J, Lindor N, and Couch FJ. (October 2008) Evaluation of Cancer Causality of BRCA2 Variants of Uncertain Significance. Balfour Surgical Symposium, Mayo Clinic; Rochester, MN.
Farrugia DJ, Diego EJ, Soran A, McAuliffe PF, Landmann A, Bonaventura M, Johnson RR, Ahrendt GM. (November 2015) Institutional Experience of Applying ACOSOG Z0011 Criteria to Breast Cancer Patients Under-Represented in the Z0011 Trial. Women’s Cancer Research Center Retreat, Nemacolin, PA.
Farrugia DJ, Diego EJ, Soran A, McAuliffe PF, Landmann A, Bonaventura M, Johnson RR, Ahrendt GM. Institutional Experience of Applying ACOSOG Z0011 Criteria to Breast Cancer Patients Under-Represented in the Z0011 Trial (ASBrS Annual Meeting in Dallas, April 2016)
Farrugia DJ, Landmann A, Diego EJ, McAuliffe PF, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Puhalla S, Jankowitz R, Brufsky A, Lembersky B, Rastogi P, Davidson NE, Ahrendt GA, Bhargava R. Utilization of Magee Equation 3 in ER Positive, HER2 Negative/Equivocal tumors to Determine Pathologic Response to Neoadjuvant Therapy. (Department of Surgery Research Day, Pittsburgh, May 2016)
Farrugia DJ, Landmann A, Diego EJ, McAuliffe PF, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Puhalla S, Jankowitz R, Brufsky A, Lembersky B, Rastogi P, Davidson NE, Ahrendt GA, Bhargava R. Utilization of Magee Equation 3 in ER Positive, HER2 Negative/Equivocal tumors to Determine Pathologic Response to Neoadjuvant Therapy. (ASCO annual meeting, Chicago; June 2016)
Farrugia DJ, Landmann A, Diego EJ, McAuliffe PF, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Clark B, Puhalla S, Brufsky A, Jankowitz R, Lembersky B, Davidson NE, Ahrendt GA, Bhargava R. Mitotic Index Predicts Breast Cancer Recurrence after Neoadjuvant Systemic Therapy. (ASCO Annual Meeting, Chicago; Jun 2016)
Landmann A, Farrugia DJ, Diego EJ, Bonaventura M, Soran A, Bonaventura M, Johnson R, Dabbs DJ, Clark B, Puhalla S, Brufsky A, Davidson NE, Lembersky B, Jankowitz R, Puhalla S, Ahrendt GA, McAuliffe PF, Bhargava R. HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2 positive or HER2 negative tumors? (ASCO annual meeting, Chicago, Jun 2016)
Landmann A, Farrugia DJ, Diego EJ, Bonaventura M, Soran A, Johnson R, Bonaventura M, Dabbs DJ, Clark B, Puhalla S, Brufsky A, Lembersky B, Jankowitz R, Puhalla S, Ahrendt GA, McAuliffe PF, Bhargava R. Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease? (ASCO annual meeting, Chicago, Jun 2016)
Farrugia DJ, Landmann A, McAuliffe PF, Diego EJ, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Clark B, Lembersky B, Puhalla S, Brufsky A, Jankowitz R, Davidson NE, Ahrendt GA, Bhargava R. Prognostic significance of modified Residual Disease in Breast and Nodes (mRDBN) algorithm after neoadjuvant chemotherapy for breast cancer. (San Antonio Breast Cancer Symposium, San Antonio, Dec 2016)
Lee J, Diego EJ, Soran A, Farrugia DJ, Landmann, A, Bonaventura MB; Johnson R, McAuliffe PF, Ahrendt GM. Neoadjuvant Chemotherapy Increases Breast Conservation Rates and Decreases Extent of Axillary Surgery in Patients with Estrogen Receptor Positive Breast Cancer. (submitted for Society of Surgical Oncology Annual Cancer Symposium, Seattle 2017)
I had Awake Liposuction on my abdomen, hips, and back bra rolls on a Wednesday, and the experience was fantastic. The procedure was pain-free with minimal discomfort, and the nurses made me feel so comfortable. I was even able to return to work by Monday, which made recovery easy to manage.